This systematic review aims to evaluate the effects of GLP-1 RAs compared with standard care on the risks of diabetic retinopathy and diabetic nephropathy in patients with type 2 diabetes, focusing on evidence from randomized clinical trials. This evidence concerns the gene GCG and diabetic kidney disease.